169 related articles for article (PubMed ID: 38135694)
1. Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
Ferrari MG; Jimenez-Uribe AP; Wang L; Hoeppner LH; Murugan P; Hahm E; Yu J; Kuzel TM; Gradilone SA; Mansini AP
Oncogene; 2024 Feb; 43(7):484-494. PubMed ID: 38135694
[TBL] [Abstract][Full Text] [Related]
2. Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target.
Ferrari M; Wang L; Hoeppner L; Hahm E; Yu J; Kuzel T; Mansini A
Res Sq; 2023 Jun; ():. PubMed ID: 37333086
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of miR-141-3p promotes bone metastasis via activating NF-κB signaling in prostate cancer.
Huang S; Wa Q; Pan J; Peng X; Ren D; Huang Y; Chen X; Tang Y
J Exp Clin Cancer Res; 2017 Dec; 36(1):173. PubMed ID: 29202848
[TBL] [Abstract][Full Text] [Related]
4. High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-κB signaling pathway.
Zhang J; Shao S; Han D; Xu Y; Jiao D; Wu J; Yang F; Ge Y; Shi S; Li Y; Wen W; Qin W
Int J Oncol; 2018 Aug; 53(2):659-671. PubMed ID: 29845254
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
[TBL] [Abstract][Full Text] [Related]
6. Identifying and treating ROBO1
Ferrari MG; Ganaie AA; Shabenah A; Mansini AP; Wang L; Murugan P; Davicioni E; Wang J; Deng Y; Hoeppner LH; Warlick CA; Konety BR; Saleem M
Prostate; 2020 Sep; 80(13):1045-1057. PubMed ID: 32687658
[TBL] [Abstract][Full Text] [Related]
7.
Ganaie AA; Beigh FH; Astone M; Ferrari MG; Maqbool R; Umbreen S; Parray AS; Siddique HR; Hussain T; Murugan P; Morrissey C; Koochekpour S; Deng Y; Konety BR; Hoeppner LH; Saleem M
Clin Cancer Res; 2018 Dec; 24(24):6421-6432. PubMed ID: 30087142
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of the TLR4 co-receptor, MD2, prevents colon cancer growth and lung metastasis.
Rajamanickam V; Yan T; Xu S; Hui J; Xu X; Ren L; Liu Z; Liang G; Wang O; Wang Y
Int J Biol Sci; 2020; 16(8):1288-1302. PubMed ID: 32210720
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA expression profiles in the progression of prostate cancer--from high-grade prostate intraepithelial neoplasia to metastasis.
Leite KR; Tomiyama A; Reis ST; Sousa-Canavez JM; Sañudo A; Camara-Lopes LH; Srougi M
Urol Oncol; 2013 Aug; 31(6):796-801. PubMed ID: 21880514
[TBL] [Abstract][Full Text] [Related]
11. Silencing
Xiao L; Peng H; Yan M; Chen S
DNA Cell Biol; 2021 Nov; 40(11):1445-1455. PubMed ID: 34767732
[No Abstract] [Full Text] [Related]
12. A PSCA/PGRN-NF-κB-Integrin-α4 Axis Promotes Prostate Cancer Cell Adhesion to Bone Marrow Endothelium and Enhances Metastatic Potential.
Zhao Z; Li E; Luo L; Zhao S; Liu L; Wang J; Kang R; Luo J
Mol Cancer Res; 2020 Mar; 18(3):501-513. PubMed ID: 31722969
[TBL] [Abstract][Full Text] [Related]
13. Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis.
Chien MH; Lin YW; Wen YC; Yang YC; Hsiao M; Chang JL; Huang HC; Lee WJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):246. PubMed ID: 31182131
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of myeloid differentiation factor 2 by baicalein protects against acute lung injury.
Chen H; Zhang Y; Zhang W; Liu H; Sun C; Zhang B; Bai B; Wu D; Xiao Z; Lum H; Zhou J; Chen R; Liang G
Phytomedicine; 2019 Oct; 63():152997. PubMed ID: 31254764
[TBL] [Abstract][Full Text] [Related]
15. The twist box domain is required for Twist1-induced prostate cancer metastasis.
Gajula RP; Chettiar ST; Williams RD; Thiyagarajan S; Kato Y; Aziz K; Wang R; Gandhi N; Wild AT; Vesuna F; Ma J; Salih T; Cades J; Fertig E; Biswal S; Burns TF; Chung CH; Rudin CM; Herman JM; Hales RK; Raman V; An SS; Tran PT
Mol Cancer Res; 2013 Nov; 11(11):1387-400. PubMed ID: 23982216
[TBL] [Abstract][Full Text] [Related]
16. P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.
Maynard JP; Lu J; Vidal I; Hicks J; Mummert L; Ali T; Kempski R; Carter AM; Sosa RY; Peiffer LB; Joshu CE; Lotan TL; De Marzo AM; Sfanos KS
J Pathol; 2022 Feb; 256(2):149-163. PubMed ID: 34652816
[TBL] [Abstract][Full Text] [Related]
17. NF-κB gene signature predicts prostate cancer progression.
Jin R; Yi Y; Yull FE; Blackwell TS; Clark PE; Koyama T; Smith JA; Matusik RJ
Cancer Res; 2014 May; 74(10):2763-72. PubMed ID: 24686169
[TBL] [Abstract][Full Text] [Related]
18. MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway.
Yang Q; Lang C; Wu Z; Dai Y; He S; Guo W; Huang S; Du H; Ren D; Peng X
J Exp Clin Cancer Res; 2019 Sep; 38(1):391. PubMed ID: 31488180
[TBL] [Abstract][Full Text] [Related]
19. miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer.
Gururajan M; Josson S; Chu GC; Lu CL; Lu YT; Haga CL; Zhau HE; Liu C; Lichterman J; Duan P; Posadas EM; Chung LW
Clin Cancer Res; 2014 Dec; 20(24):6559-69. PubMed ID: 25324143
[TBL] [Abstract][Full Text] [Related]
20. ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models.
Parray A; Siddique HR; Kuriger JK; Mishra SK; Rhim JS; Nelson HH; Aburatani H; Konety BR; Koochekpour S; Saleem M
Int J Cancer; 2014 Dec; 135(11):2493-506. PubMed ID: 24752651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
